Elacestrant

Healio spoke with Paolo Tarantino, MD, about treatments in the pipeline for metastatic breast cancer.

Healio spoke with Paolo Tarantino, MD, about FDA approvals in metastatic breast cancer.

Healio spoke with Eleonora Teplinsky, MD, about research on circulating tumor DNA in breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about recent advancements in metastatic breast cancer.

In this video, Paolo Tarantino, MD, discusses findings from the EMERALD phase 3 trial presented at San Antonio Breast Cancer Symposium.

The FDA approved elacestrant for certain patients with advanced or metastatic breast cancer.

SAN ANTONIO — Longer duration of cyclin-dependent kinase 4/6 inhibitor therapy in the metastatic setting appeared associated with extended PFS among elacestrant-treated patients with advanced breast cancer, according to study results.

Endocrine therapies have revolutionized the field of breast cancer, with significant improvements in survival outcomes among patients with hormone receptor-positive disease.

The FDA granted priority review to elacestrant for ER-positive, HER2-negative advanced or metastatic breast cancer.

Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, spoke with Healio about a recent study on elacestrant.